In some cases, a patient with a serious or immediately life-threatening disease might be interested in an investigational therapy, but the patient does not qualify for an ongoing clinical trial. These patients may be able to gain access to investigational therapies from Seagen. This practice is commonly called “compassionate use” or “expanded access.”Download Overview
Criteria for compassionate use
We base all decisions about compassionate use solely on clinical evidence. These decisions are guided by criteria that are generally accepted by the pharmaceutical and biotechnology industry.
Compassionate use may be appropriate if all of the following apply:
Additionally, compassionate use must not interfere with the development of the investigational product or slow the company’s ability to broadly deliver the therapy to patients. Seagen must also have adequate supply of the investigational therapy.
How to request compassionate use
All requests must be submitted by a physician. If you are a patient and believe that an investigational therapy may be helpful for you, please speak with the physician who is treating your cancer.
Requests should be submitted to our Medical Affairs department at firstname.lastname@example.org. We evaluate all requests promptly and will respond within 48 hours.